RxDoctor Payments Data

Steven Langdon, MD

Family Medicine · Lawrenceburg, INNPI 1760451058

Payments from drug & device makers

$190in general payments, 2019–2025

Across 11 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$63
  • Lilly USA, LLC$31
  • AstraZeneca$18
  • Amgen$17
  • Sanofi Pasteur Inc.$16
  • Novo Nordisk$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$63
Lilly USA, LLC2$31
AstraZeneca1$18
Amgen1$17
Sanofi Pasteur Inc.1$16
Novo Nordisk1$16
Pfizer1$15
AbbVie1$14

How this compares

$190 in reported general payments places this provider in the 30th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$131,870
Medicare patients
233
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$150,385
TrulicityDulaglutide74$133,325
OzempicSemaglutide74$122,545
JardianceEmpagliflozin50$74,270
JanuviaSitagliptin Phosphate48$49,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$34,988
Victoza 3-PakLiraglutide15$29,676
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$25,580
MounjaroTirzepatide14$18,685
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,945
RybelsusSemaglutide11$14,427
Spiriva RespimatTiotropium Bromide23$13,878
Spiriva HandihalerTiotropium Bromide22$11,518
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,295
SymbicortBudesonide/Formoterol Fumarate24$7,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$31$152,01088 claims
PfizerEliquis$15$150,385156 claims
Novo NordiskOzempic, Rybelsus$16$136,97285 claims
GSKTrelegy Ellipta, Anoro Ellipta$63$51,93371 claims
AstraZenecaBreztri Aerosphere, Symbicort, Farxiga$18$24,46353 claims
AbbVieSynthroid$14$1,04717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lawrenceburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →